Lulling the Cancer Cell into an Eternal Sleep

por Farrington, Caroline C., Narla, Goutham
Publicado no Cancer Res (2019)

Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis

por O’Connor, Caitlin M., Narla, Goutham
Publicado no Cancer Discov (2020)

The impact of phosphatases on proliferative and survival signaling in cancer

por Narla, Goutham, Sangodkar, Jaya, Ryder, Christopher B.
Publicado no Cell Mol Life Sci (2018)

Krüppel Cripples Prostate Cancer : KLF6 Progress and Prospects

por Narla, Goutham, Friedman, Scott L., Martignetti, John A.
Publicado em 2003

Emerging Roles of Kruppel-Like Factor 6 and Kruppel-Like Factor 6 Splice Variant 1 in Ovarian Cancer Progression and Treatment

por DiFeo, Analisa, Narla, Goutham, Martignetti, John A.
Publicado em 2009

Targeting PP2A in cancer: Combination therapies

por Mazhar, Sahar, Taylor, Sarah E., Sangodkar, Jaya, Narla, Goutham
Publicado no Biochim Biophys Acta Mol Cell Res (2018)

Therapeutic Targeting of PP2A

por O’Connor, Caitlin M., Perl, Abbey, Leonard, Daniel, Sangodkar, Jaya, Narla, Goutham
Publicado no Int J Biochem Cell Biol (2017)

Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr(307) on PP2Ac

por Mazhar, Sahar, Leonard, Daniel, Sosa, Alejandro, Schlatzer, Daniela, Thomas, Dafydd, Narla, Goutham
Publicado no Cell Rep (2020)

Protein phosphatase 2A Aα regulates Aβ protein expression and stability

por O'Connor, Caitlin M., Hoffa, Matthew T., Taylor, Sarah E., Avelar, Rita A., Narla, Goutham
Publicado no J Biol Chem (2019)

Kruppel-like Transcription Factor 6 Regulates Inflammatory Macrophage Polarization

por Date, Dipali, Das, Riku, Narla, Goutham, Simon, Daniel I., Jain, Mukesh K., Mahabeleshwar, Ganapati H.
Publicado em 2014

All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase

por Sangodkar, Jaya, Farrington, Caroline, McClinch, Kimberly, Galsky, Matthew D., Kastrinsky, David B., Narla, Goutham
Publicado no FEBS J (2015)

Reengineered tricyclic anti-cancer agents

por Kastrinsky, David B., Sangodkar, Jaya, Zaware, Nilesh, Izadmehr, Sudeh, Dhawan, Neil S., Narla, Goutham, Ohlmeyer, Michael
Publicado no Bioorg Med Chem (2015)

Tumor suppressor Activity of KLF6 Mediated by Downregulation of the PTTG1 Oncogene

por Lee, Ursula E., Ghiassi-Nejad, Zahra, Paris, Andrew, Yea, Steven, Narla, Goutham, Walsh, Martin, Friedman, Scott L.
Publicado em 2010

A Functional Role for KLF6-SV1 in Lung Adenocarcinoma Prognosis and Chemotherapy Response

por DiFeo, Analisa, Feld, Lauren, Rodriguez, Estefania, Wang, Christine, Beer, David G., Martignetti, John A., Narla, Goutham
Publicado em 2008

KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3-Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer Model

por DiFeo, Analisa, Huang, Fei, Sangodkar, Jaya, Terzo, Esteban A., Leake, Devin, Narla, Goutham, Martignetti, John A.
Publicado em 2009

Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series

por Lee, Richard T., Yang, Peiying, Alahmadi, Asrar, McQuade, Jennifer, Yuan, Eric, Difeo, Analisa, Narla, Goutham, Kaseb, Ahmed
Publicado no Case Rep Oncol (2021)

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma

por Sangodkar, Jaya, DiFeo, Analisa, Feld, Lauren, Bromberg, Romina, Huang, Fei, Terzo, Esteban A., Choudhri, Aisha, Narla, Goutham
Publicado em 2009

Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45)

por Perl, Abbey L., O'Connor, Caitlin M., Fa, Pengyan, Mayca Pozo, Franklin, Zhang, Junran, Zhang, Youwei, Narla, Goutham
Publicado no J Biol Chem (2019)

Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy

por Tian, Danmei, Tang, Jinshan, Geng, Xinran, Li, Qingwen, Wang, Fangfang, Zhao, Huadong, Narla, Goutham, Yao, Xinsheng, Zhang, Youwei
Publicado no Cancer Lett (2020)

Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, Nuclear Factor-kappa B, and Cell Cycle Progression in Non-Small Cell Lung Cancer

por Tai Dermawan, Josephine Kam, Gurova, Katerina, Pink, John, Dowlati, Afshin, De, Sarmishtha, Narla, Goutham, Sharma, Neelesh, Stark, George R.
Publicado em 2014